Protective effects of fluvoxamine against ischemia/reperfusion injury in isolated, perfused guinea-pig hearts

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 5, 2014, Pages 731-739

  Muto, Tatsuya ^a,b   Usuda, Haruki ^a   Yamamura, Aya ^a   Yoshida, Koji ^a   Ohashi, Ai ^a   Mitsui Saitoh, Kumiko ^a,c   Sakai, Junichi ^a,c   Sugimoto, Yumi ^d   Mizutani, Hideki ^a   Nonogaki, Tsunemasa ^a   Hotta, Yoshihiro ^a,e  

^a KINJO GAKUIN UNIVERSITY   (Japan)

^b Meitetsu Hospital   (Japan)

^c NAGOYA GAKUIN UNIVERSITY   (Japan)

^d YOKOHAMA COLLEGE OF PHARMACY   (Japan)

^e AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Fluvoxamine; Ischemia reperfusion injury; Left ventricular developed pressure; Mitochondrial permeability transition pore (MPTP)

Indexed keywords

CALCIUM ION; CASPASE 3; FLUVOXAMINE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; SEROTONIN; ATRACTYLOSIDE; CALCIUM; SEROTONIN UPTAKE INHIBITOR;

ACIDIFICATION; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GUINEA PIG; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; MALE; MITOCHONDRION; NONHUMAN; REPERFUSION INJURY; ANIMAL; CYTOLOGY; DRUG EFFECTS; HEART; HEART MUSCLE; HEART VENTRICLE PRESSURE; IN VITRO STUDY; METABOLISM; PERFUSION;

ANIMALS; APOPTOSIS; ATRACTYLOSIDE; CALCIUM; CASPASE 3; FLUVOXAMINE; GUINEA PIGS; HEART; IN VITRO TECHNIQUES; MITOCHONDRIA; MYOCARDIUM; PERFUSION; REPERFUSION INJURY; SEROTONIN UPTAKE INHIBITORS; VENTRICULAR PRESSURE;

EID: 84899858496     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00552     Document Type: Article

References (43)

1. Frishman WH, Grewall P. Serotonin and the heart. Ann. Med., 32, 195-209 (2000).
2. Villalón CM, Heiligers JP, Centurión D, De Vries P, Saxena PR. Characterization of putative 5- HT7 receptors mediating tachycardia in the cat. Br. J. Pharmacol., 121, 1187-1195 (1997).
3. Brogden RN, Sorkin EM. Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. Drugs, 40, 903-949 (1990).
4. 2) receptor antagonists in ischemic rat hearts. J. Cardiovasc. Pharmacol., 22, 664-672 (1993).
5. Grover GJ, Parham CS, Youssef S, Ogletree ML. Protective effect of the serotonin receptor antagonist cinanserin in two canine models of pacing-induced myocardial ischemia. Pharmacology, 50, 286-297 (1995).
6. 2A antagonist, against postischemic myocardial dysfunction in guinea-pig heart. Mol. Cell. Biochem., 272, 119-132 (2005).
7. Läer S, Remmers F, Scholz H, Stein B, Ulrich Müller F, Neumann J. Receptor mechanisms involved in the 5-HT-induced inotropic action in the rat isolated atrium. Br. J. Pharmacol., 123, 1182-1188 (1998).
8. 2B receptor signaling. FASEB J., 17, 1373-1375 (2003).
9. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat. Med., 6, 513-519 (2000).
10. Gill C, Mestril R, Samali A. Losing heart. the role of apoptosis in heart disease - A novel therapeutic target? FASEB J., 16, 135-146 (2002).
11. Huang L, Hotta Y, Miyazeki K, Ishikawa N, Miki Y, Sugimoto Y, Yamada J, Nakano A, Nishiwaki K, Shimada Y. Different effects of optical isomers of the 5-HT1A receptor antagonist pyrapyridolol against postischemic guinea-pig myocardial dysfunction and apoptosis through the mitochondrial permeability transition pore. Eur. J. Pharmacol., 534, 165-177 (2006).
12. Griffiths EJ, Ocampo CJ, Savage JS, Stern MD, Silverman HS. Protective effects of low and high doses of cyclosporin A against reoxygenation injury in isolated rat cardiomyocytes are associated with differential effects on mitochondrial calcium levels. Cell Calcium, 27, 87-95 (2000).
13. Hausenloy D, Wynne A, Duchen M, Yellon D. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation, 109, 1714-1717 (2004).
14. Serafeim A, Grafton G, Chamba A, Gregory CD, Blakely RD, Bowery NG, Barnes NM, Gordon J. 5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. Blood, 99, 2545-2553 (2002).
15. 23Na NMR signals in perfused guinea-pig heart induced by dihydroouabain and grayanotoxin-I. Mol. Cell. Biochem., 139, 59-70 (1994).
16. Koike A, Akita T, Hotta Y, Takeya K, Kodama I, Murase M, Abe T, Toyama J. Protective effects of dimethyl amiloride against postischemic myocardial dysfunction in rabbit hearts: phosphorus 31-nuclear magnetic resonance measurements of intracellular pH and cellular energy. J. Thorac. Cardiovasc. Surg., 112, 765-775 (1996).
17. Cao Y, Hotta Y, Shioi K, Nagata Y, Kawai N, Ishikawa N. Protective effects of FK409, a novel nitric oxide donor, against postischemic myocardial dysfunction in guinea-pig hearts. J. Cardiovasc. Pharmacol., 38, 593-605 (2001).
18. Hotta Y, Nagatsu A, Liu W, Muto T, Narumiya C, Lu X, Yajima M, Ishikawa N, Miyazeki K, Kawai N, Mizukami H, Sakakibara J. Protective effects of antioxidative serotonin derivatives isolated from safflower against postischemic myocardial dysfunction. Mol. Cell. Biochem., 238, 151-162 (2002).
19. + exchange inhibitors on cardiac function and apoptosis in guinea-pig ischemiareperfused hearts. Eur. J. Pharmacol., 503, 109-122 (2004).
20. + antiport in heart mitochondria. J. Biol. Chem., 259, 14672-14678 (1984).
21. Hotta Y, Fujita M, Nakagawa J, Ando H, Takeya K, Ishikawa N, Sakakibara J. The contribution of cytosolic ionic and energetic milieu change to ischemia- and reperfused-induced injury in guineapig heart: Fluorometry and nuclear magnetic resonance studies. J. Cardiovasc. Pharmacol., 31, 146-156 (1998).
22. Hotta Y, Otsuka-Murakami H, Fujita M, Nakagawa J, Yajima M, Liu W, Ishikawa N, Kawai N, Masumizu T, Kohno M. Protective role of nitric oxide synthase against ischemia-reperfusion injury in guinea pigs myocardial mitochondria. Eur. J. Pharmacol., 380, 37-48 (1999).
23. Hirai M, Hotta Y, Ishikawa N, Wakida Y, Fukuzawa Y, Isobe F, Nakano A, Chiba T, Kawamura N. Protective effects of EGCg or GCg, a green tea catechin epimer, against postischemic myocardial dysfunction in guinea pig hearts. Life Sci., 80, 1020-1032 (2007).
24. Itoh G, Tamura J, Suzuki M, Suzuki Y, Ikeda H, Koike M, Nomura M, Jie T, Ito K. DNA fragmentation of human infarcted myocardial cells demonstrated by the nick end labeling method and DNA agarose gel electrophoresis. Am. J. Pathol., 146, 1325-1331 (1995).
25. Tong J, Cao Y, Hotta Y, Ishikawa N, Takeo T, Nishimaki H, Masuda K, Yang CL, Kasai K, Ikeda H, Itoh G. Cardiomyocite apoptosis induced in Langendorff preparation of isolated guinea-pig heart perfused with Krebs-Henseleit solution deprived of glucose, with and without oxygen supply. Basic Appl. Myol., 11, 145-152 (2002).
26. Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A. Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J. Exp. Med., 183, 1957-1964 (1996).
27. Takano S. Role of 5-hydroxytryptamine in platelet thrombus formation and mechanisms of inhibition of thrombus formation by 5-hydroxytryptamine 2A antagonists in rabbits. Arch. Int. Pharmacodyn. Ther., 330, 297-308 (1995).
28. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol., 372, 49-56 (1999).
29. Shimizu Y, Minatoguchi S, Hashimoto K, Uno Y, Arai M, Wang N, Chen X, Lu C, Takemura G, Shimomura M, Fujiwara T, Fujiwara H. The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts. J. Am. Coll. Cardiol., 40, 1347-1355 (2002).
30. Niwa M, Kunisada K, Himeno A, Kawaguchi A, Ozaki M. 5-hydroxytryptamine content in the rat heart: quantitation by highperformance liquid chromatographic electrochemical detection. Jpn. J. Pharmacol., 34, 264-267 (1984).
31. Teramoto Y, Urano T, Nagai N, Takada Y, Ikeda K, Takada A. Plasma levels of 5-HT and 5-HIAA increased after intestinal ischemia/reperfusion in rats. Jpn. J. Physiol., 48, 333-339 (1998).
32. Takano S, Hoshino Y, Li L, Matsuoka I, Ono T, Kimura J. Dual roles of 5-hydroxytryptamine in ischemia-reperfusion injury in isolated rat hearts. J. Cardiovasc. Pharmacol. Ther., 9, 43-50 (2004).
33. Xu N, Qiu C, Wang W, Wang Y, Chai C, Yan Y, Zhu D. HPLC/MS/MS for quantification of two types of neurotransmitters in rat brain and application: myocardial ischemia and protection of Sheng-Mai San. J. Pharm. Biomed. Anal., 55, 101-108 (2011).
34. van den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation, 79, 116-124 (1989).
35. Rajesh KG, Suzuki R, Maeda H, Murio Y, Sasaguri S. 5- HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury. Life Sci., 79, 1749-1755 (2006).
36. 2A receptors by sarpogrelate protects the heart against myocardial infarction in rats. J. Cardiovasc. Pharmacol. Ther., 7, 53-59 (2002).
37. 1A-receptors. J. Physiol. Pharmacol., 53, 615-624 (2002).
38. 1B receptor in hypoperfused canine hearts. J. Mol. Cell. Cardiol., 37, 1219-1223 (2004).
39. Müller BA, Dhalla NS. Mechanisms of the beneficial actions of ischemic preconditioning on subcellular remodeling in ischemicreperfused heart. Curr. Cardiol. Rev., 6, 255-264 (2010).
40. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu. Rev. Physiol., 60, 619-642 (1998).
41. Green DR, Reed JC. Mitochondria and apoptosis. Science, 281, 1309-1312 (1998).
42. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann. N. Y. Acad. Sci., 993, 334-344, discussion, 345-349 (2003).
43. De Maeyer JH, Straetemans R, Schuurkes JA, Lefebvre RA. Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development. Br. J. Pharmacol., 147, 140-157 (2006).